You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePonatinib
Accession NumberDB08901
TypeSmall Molecule
GroupsApproved
DescriptionPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Structure
Thumb
Synonyms
AP 24534
AP24534
Ponatinibum
External Identifiers
  • AP24534
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Iclusigtablet, film coated30 mg/1oralARIAD Pharmaceuticals, Inc.2015-04-22Not applicableUs
Iclusigtablet45 mgoralAriad Pharmaceuticals Inc2016-01-07Not applicableCanada
Iclusigtablet, film coated45 mg/1oralARIAD Pharmaceuticals, Inc.2012-12-14Not applicableUs
Iclusigtablet, film coated15 mg/1oralARIAD Pharmaceuticals, Inc.2012-12-14Not applicableUs
Iclusigtablet15 mgoralAriad Pharmaceuticals Inc2015-08-21Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ponatinib Hydrochloride
Thumb
  • InChI Key: BWTNNZPNKQIADY-UHFFFAOYSA-N
  • Monoisotopic Mass: 568.19652187
  • Average Mass: 569.02
DBSALT000142
Categories
UNII4340891KFS
CAS number943319-70-8
WeightAverage: 532.5595
Monoisotopic: 532.219844131
Chemical FormulaC29H27F3N6O
InChI KeyInChIKey=PHXJVRSECIGDHY-UHFFFAOYSA-N
InChI
InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)
IUPAC Name
3-(2-{imidazo[1,2-b]pyridazin-3-yl}ethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide
SMILES
CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-phenylbenzamides. These are benzamides that are N-linked to a phenyl group via the carboxamide group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzamides
Direct ParentN-phenylbenzamides
Alternative Parents
Substituents
  • N-phenylbenzamide
  • N-arylamide
  • Benzoic acid or derivatives
  • Phenylmethylamine
  • Benzylamine
  • Benzoyl
  • Aralkylamine
  • N-alkylpiperazine
  • N-methylpiperazine
  • Toluene
  • Pyridazine
  • Piperazine
  • N-substituted imidazole
  • 1,4-diazinane
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationPonatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
PharmacodynamicsNot Available
Mechanism of actionPonatinib is a multi-target kinase inhibitor. Its primary cellular target is the Bcr-Abl tyrosine kinase protein which is constitutively active and promotes the progression of CML. This protein arises from the fused Bcr and Abl gene- what is commonly known as the Philadelphia chromosome. Ponatinib is unique in that it is especially useful in the treatment of resistant CML because it inhibits the tyrosine kinase activity of Abl and T315I mutant kinases. The T315I mutation confers resistance in cells as it prevents other Bcr-Abl inhibitors from binding to the Abl kinase. Other targets that ponatinib inhibits are members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3. A decrease in tumour size expressing native or T315I mutant BCR-ABL have been observed in rats.
Related Articles
AbsorptionThe absolute bioavailability of ponatinib is unknown. Peak concentrations of ponatinib are observed within 6 hours after Iclusig oral administration. Food does not affect absorption of food. The aqueous solubility of ponatinib is pH dependent, with higher pH resulting in lower solubility. When 45 mg of ponatinib is given to cancer patients, the pharmacokinetic parameters are as follows: Cmax = 73 ng/mL; AUC = 1253 ng•hr/mL;
Volume of distribution

After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the steady state volume of distribution is 1223 L. Ponatinib is a weak substrate for P-gp and ABCG2.

Protein binding> 99% bound to plasma proteins.
Metabolism

At least 64% of a ponatinib dose undergoes phase I and phase II metabolism. CYP3A4 and to a lesser extent CYP2C8, CYP2D6 and CYP3A5 are involved in the phase I metabolism of ponatinib in vitro. Ponatinib is also metabolized by esterases and/or amidases.

Route of eliminationPonatinib is mainly eliminated via feces. Following a single oral dose of [14C]-labeled ponatinib, approximately 87% of the radioactive dose is recovered in the feces and approximately 5% in the urine.
Half lifeAfter oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).
ClearanceNot Available
ToxicityThe most common non-hematologic adverse reactions (≥ 20%) were hypertension, rash, abdominal pain, fatigue, headache, dry skin, constipation, arthralgia, nausea, and pyrexia. Hematologic adverse reactions included thrombocytopenia, anemia, neutropenia, lymphopenia, and leukopenia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9444
Caco-2 permeable-0.5985
P-glycoprotein substrateSubstrate0.7205
P-glycoprotein inhibitor IInhibitor0.8197
P-glycoprotein inhibitor IIInhibitor0.9125
Renal organic cation transporterInhibitor0.5
CYP450 2C9 substrateNon-substrate0.8612
CYP450 2D6 substrateNon-substrate0.7047
CYP450 3A4 substrateSubstrate0.7636
CYP450 1A2 substrateNon-inhibitor0.8592
CYP450 2C9 inhibitorNon-inhibitor0.6804
CYP450 2D6 inhibitorNon-inhibitor0.764
CYP450 2C19 inhibitorInhibitor0.5563
CYP450 3A4 inhibitorNon-inhibitor0.5613
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6686
Ames testNon AMES toxic0.5331
CarcinogenicityNon-carcinogens0.8254
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8377 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8253
hERG inhibition (predictor II)Inhibitor0.7493
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral15 mg
Tabletoral45 mg
Tablet, film coatedoral15 mg/1
Tablet, film coatedoral30 mg/1
Tablet, film coatedoral45 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8114874 No2006-12-222026-12-22Us
US9029533 No2006-12-222026-12-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
pKa2.77 and 7.8 FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.00295 mg/mLALOGPS
logP3.94ALOGPS
logP4.97ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)11.36ChemAxon
pKa (Strongest Basic)8.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area65.77 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity152.63 m3·mol-1ChemAxon
Polarizability55.69 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Reddy EP, Aggarwal AK: The ins and outs of bcr-abl inhibition. Genes Cancer. 2012 May;3(5-6):447-54. doi: 10.1177/1947601912462126. [PubMed:23226582 ]
External Links
ATC CodesL01XE24
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (295 KB)
MSDSDownload (98 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Ponatinib can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Ponatinib.
AcetaminophenThe serum concentration of Ponatinib can be increased when it is combined with Acetaminophen.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ponatinib.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Ponatinib.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ponatinib.
AlbendazoleThe serum concentration of Ponatinib can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Ponatinib can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Ponatinib.
AlectinibThe serum concentration of Ponatinib can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Ponatinib can be increased when it is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Ponatinib.
AmantadineThe serum concentration of Ponatinib can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Ponatinib.
Aminohippuric acidThe serum concentration of Ponatinib can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Ponatinib can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Ponatinib can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Ponatinib can be increased when it is combined with Amlodipine.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Ponatinib.
AmprenavirThe serum concentration of Ponatinib can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Ponatinib can be increased when it is combined with Amsacrine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Ponatinib.
AprepitantThe serum concentration of Ponatinib can be increased when it is combined with Aprepitant.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Ponatinib.
ArtemetherThe metabolism of Ponatinib can be decreased when combined with Artemether.
AstemizoleThe serum concentration of Ponatinib can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Ponatinib can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Ponatinib can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Ponatinib can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Ponatinib can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ponatinib.
AzelastineThe serum concentration of Ponatinib can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Ponatinib can be increased when it is combined with Azithromycin.
BenzocaineThe serum concentration of Ponatinib can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Ponatinib can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Ponatinib.
BetaxololThe metabolism of Ponatinib can be decreased when combined with Betaxolol.
BevacizumabBevacizumab may increase the cardiotoxic activities of Ponatinib.
BexaroteneThe serum concentration of Ponatinib can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Ponatinib can be increased when it is combined with Biperiden.
BoceprevirThe serum concentration of Ponatinib can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Ponatinib can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Ponatinib can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ponatinib.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ponatinib.
BromocriptineThe serum concentration of Ponatinib can be increased when it is combined with Bromocriptine.
BuprenorphineThe serum concentration of Ponatinib can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Ponatinib can be decreased when combined with Bupropion.
BuspironeThe serum concentration of Ponatinib can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Ponatinib can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Ponatinib can be increased when it is combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Ponatinib.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Ponatinib.
CandesartanThe serum concentration of Ponatinib can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Ponatinib can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Ponatinib can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Ponatinib.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Ponatinib.
CarvedilolThe serum concentration of Ponatinib can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Ponatinib can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Ponatinib can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Ponatinib can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ponatinib.
ChloroquineThe serum concentration of Ponatinib can be increased when it is combined with Chloroquine.
ChlorpromazineThe serum concentration of Ponatinib can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Ponatinib can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Ponatinib can be increased when it is combined with Chlorprothixene.
CholecalciferolThe metabolism of Ponatinib can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Ponatinib can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Ponatinib can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Ponatinib can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Ponatinib can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Ponatinib.
CinacalcetThe metabolism of Ponatinib can be decreased when combined with Cinacalcet.
CiprofloxacinThe serum concentration of Ponatinib can be increased when it is combined with Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Ponatinib.
CitalopramThe serum concentration of Ponatinib can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Ponatinib can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Ponatinib can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Ponatinib.
ClobazamThe metabolism of Ponatinib can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Ponatinib can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Ponatinib.
ClomipramineThe serum concentration of Ponatinib can be increased when it is combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Ponatinib.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Ponatinib.
ClopidogrelThe metabolism of Ponatinib can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Ponatinib can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Ponatinib is combined with Clozapine.
ClozapineThe metabolism of Ponatinib can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Ponatinib can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ponatinib.
CocaineThe metabolism of Ponatinib can be decreased when combined with Cocaine.
ColchicineThe serum concentration of Ponatinib can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Ponatinib can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Ponatinib can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ponatinib.
CrizotinibThe metabolism of Ponatinib can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Ponatinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ponatinib.
CyclosporineThe metabolism of Ponatinib can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Ponatinib.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ponatinib.
DabrafenibThe serum concentration of Ponatinib can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Ponatinib.
DaclatasvirThe serum concentration of Ponatinib can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Ponatinib can be increased when it is combined with Dactinomycin.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Ponatinib.
DarifenacinThe metabolism of Ponatinib can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Ponatinib can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Ponatinib can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Ponatinib can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Ponatinib.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Ponatinib.
DeferasiroxThe serum concentration of Ponatinib can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Ponatinib can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Ponatinib can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ponatinib.
DesloratadineThe serum concentration of Ponatinib can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Ponatinib can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Ponatinib.
DextromethorphanThe serum concentration of Ponatinib can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ponatinib.
DiclofenacThe serum concentration of Ponatinib can be increased when it is combined with Diclofenac.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ponatinib.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ponatinib.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Ponatinib.
DigoxinDigoxin may decrease the cardiotoxic activities of Ponatinib.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ponatinib.
DihydroergotamineThe metabolism of Ponatinib can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Ponatinib.
DiltiazemThe metabolism of Ponatinib can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Ponatinib.
DiphenhydramineThe metabolism of Ponatinib can be decreased when combined with Diphenhydramine.
DipyridamoleThe serum concentration of Ponatinib can be increased when it is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Ponatinib.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ponatinib.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ponatinib.
DoxazosinThe serum concentration of Ponatinib can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Ponatinib can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Ponatinib can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ponatinib.
DoxycyclineThe metabolism of Ponatinib can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Ponatinib can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Ponatinib can be decreased when combined with Dronedarone.
DuloxetineThe metabolism of Ponatinib can be decreased when combined with Duloxetine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Ponatinib.
EfavirenzThe serum concentration of Ponatinib can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Ponatinib can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Ponatinib.
EliglustatThe metabolism of Ponatinib can be decreased when combined with Eliglustat.
EltrombopagThe serum concentration of Ponatinib can be increased when it is combined with Eltrombopag.
EnalaprilThe serum concentration of Ponatinib can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Ponatinib can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Ponatinib.
ErgonovineThe serum concentration of Ponatinib can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Ponatinib can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ponatinib.
ErythromycinThe metabolism of Ponatinib can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Ponatinib.
Eslicarbazepine acetateThe serum concentration of Ponatinib can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Ponatinib.
EstramustineThe serum concentration of Ponatinib can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Ponatinib can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Ponatinib.
EstroneThe serum concentration of Ponatinib can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Ponatinib.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ponatinib.
EtoposideThe serum concentration of Ponatinib can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Ponatinib can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ponatinib.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Ponatinib.
FelodipineThe serum concentration of Ponatinib can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Ponatinib can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Ponatinib.
FexofenadineThe serum concentration of Ponatinib can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Ponatinib can be increased when it is combined with Fidaxomicin.
FluconazoleThe metabolism of Ponatinib can be decreased when combined with Fluconazole.
FluoxetineThe serum concentration of Ponatinib can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Ponatinib can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Ponatinib can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Ponatinib can be increased when it is combined with Flurazepam.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ponatinib.
FluvoxamineThe metabolism of Ponatinib can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Ponatinib can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Ponatinib can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Ponatinib can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Ponatinib can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Ponatinib can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Ponatinib.
GemfibrozilThe metabolism of Ponatinib can be decreased when combined with Gemfibrozil.
GenisteinThe serum concentration of Ponatinib can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Ponatinib can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Ponatinib can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Ponatinib can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Ponatinib.
GrepafloxacinThe serum concentration of Ponatinib can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Ponatinib can be increased when it is combined with Haloperidol.
HydrocortisoneThe serum concentration of Ponatinib can be increased when it is combined with Hydrocortisone.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Ponatinib.
IdelalisibThe serum concentration of Ponatinib can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Ponatinib can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Ponatinib.
ImipramineThe serum concentration of Ponatinib can be increased when it is combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Ponatinib.
IndinavirThe serum concentration of Ponatinib can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Ponatinib.
IndomethacinThe serum concentration of Ponatinib can be increased when it is combined with Indomethacin.
IrbesartanThe metabolism of Ponatinib can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Ponatinib.
IsavuconazoniumThe metabolism of Ponatinib can be decreased when combined with Isavuconazonium.
IsoniazidThe metabolism of Ponatinib can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Ponatinib can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Ponatinib can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Ponatinib can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ponatinib can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Ponatinib can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Ponatinib.
KetoconazoleThe serum concentration of Ponatinib can be increased when it is combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Ponatinib.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Ponatinib.
LansoprazoleThe serum concentration of Ponatinib can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Ponatinib can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Ponatinib.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Ponatinib.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Ponatinib.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Ponatinib.
LevofloxacinThe serum concentration of Ponatinib can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Ponatinib.
LevothyroxineThe serum concentration of Ponatinib can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Ponatinib can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Ponatinib.
LiothyronineThe serum concentration of Ponatinib can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Ponatinib can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Ponatinib can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Ponatinib can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Ponatinib can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Ponatinib can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Ponatinib can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Ponatinib can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Ponatinib can be increased when it is combined with Losartan.
LovastatinThe metabolism of Ponatinib can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Ponatinib can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Ponatinib can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Ponatinib can be decreased when combined with Lumefantrine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Ponatinib.
MaprotilineThe serum concentration of Ponatinib can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Ponatinib can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Ponatinib can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Ponatinib can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Ponatinib can be increased when it is combined with Meprobamate.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Ponatinib.
MethadoneThe serum concentration of Ponatinib can be increased when it is combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ponatinib.
MethotrimeprazineThe metabolism of Ponatinib can be decreased when combined with Methotrimeprazine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ponatinib.
MetoprololThe serum concentration of Ponatinib can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Ponatinib can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Ponatinib can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Ponatinib can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ponatinib.
MifepristoneThe metabolism of Ponatinib can be decreased when combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Ponatinib.
MirabegronThe metabolism of Ponatinib can be decreased when combined with Mirabegron.
MitomycinThe serum concentration of Ponatinib can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Ponatinib can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Ponatinib can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Ponatinib.
ModafinilThe serum concentration of Ponatinib can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Ponatinib can be increased when it is combined with Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ponatinib.
NadololThe serum concentration of Nadolol can be increased when it is combined with Ponatinib.
NafcillinThe serum concentration of Ponatinib can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ponatinib.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Ponatinib.
NaltrexoneThe serum concentration of Ponatinib can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Ponatinib can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Ponatinib can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Ponatinib can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Ponatinib.
NeostigmineThe serum concentration of Ponatinib can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Ponatinib can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Ponatinib can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Ponatinib can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Ponatinib can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Ponatinib.
NilotinibThe metabolism of Ponatinib can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Ponatinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ponatinib.
NisoldipineThe serum concentration of Ponatinib can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Ponatinib can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Ponatinib can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Ponatinib.
NorethisteroneThe serum concentration of Ponatinib can be decreased when it is combined with Norethisterone.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Ponatinib.
OlaparibThe metabolism of Ponatinib can be decreased when combined with Olaparib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Ponatinib.
OmeprazoleThe serum concentration of Ponatinib can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Ponatinib can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Ponatinib.
P-NitrophenolThe serum concentration of Ponatinib can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Ponatinib can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Ponatinib can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Ponatinib can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Ponatinib.
PanobinostatThe metabolism of Ponatinib can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Ponatinib can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Ponatinib can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ponatinib.
Peginterferon alfa-2bThe serum concentration of Ponatinib can be decreased when it is combined with Peginterferon alfa-2b.
PentobarbitalThe serum concentration of Ponatinib can be decreased when it is combined with Pentobarbital.
PerindoprilThe serum concentration of Ponatinib can be increased when it is combined with Perindopril.
PhenobarbitalThe serum concentration of Ponatinib can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Ponatinib.
PhenytoinThe serum concentration of Ponatinib can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Ponatinib.
PimozideThe serum concentration of Ponatinib can be increased when it is combined with Pimozide.
PioglitazoneThe metabolism of Ponatinib can be decreased when combined with Pioglitazone.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ponatinib.
Platelet Activating FactorThe serum concentration of Ponatinib can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Ponatinib can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Ponatinib can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Ponatinib can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ponatinib.
PrednisoneThe serum concentration of Ponatinib can be increased when it is combined with Prednisone.
PrimidoneThe serum concentration of Ponatinib can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Ponatinib can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Ponatinib can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Ponatinib.
PromazineThe metabolism of Ponatinib can be decreased when combined with Promazine.
PromethazineThe serum concentration of Ponatinib can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Ponatinib can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Ponatinib can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Ponatinib can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ponatinib.
QuercetinThe serum concentration of Ponatinib can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Ponatinib.
QuinacrineThe serum concentration of Ponatinib can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Ponatinib can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Ponatinib can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Ponatinib can be decreased when combined with Rabeprazole.
RanitidineThe serum concentration of Ponatinib can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ponatinib.
ReboxetineThe serum concentration of Ponatinib can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Ponatinib can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Ponatinib can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Ponatinib.
RifabutinThe serum concentration of Ponatinib can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Ponatinib can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Ponatinib.
RifapentineThe serum concentration of Ponatinib can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ponatinib.
RilpivirineThe serum concentration of Ponatinib can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Ponatinib.
RitonavirThe serum concentration of Ponatinib can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Ponatinib.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Ponatinib.
RolapitantThe serum concentration of Ponatinib can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ponatinib.
RopiniroleThe metabolism of Ponatinib can be decreased when combined with Ropinirole.
RosiglitazoneThe metabolism of Ponatinib can be decreased when combined with Rosiglitazone.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Ponatinib.
SaquinavirThe serum concentration of Ponatinib can be decreased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Ponatinib.
ScopolamineThe serum concentration of Ponatinib can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Ponatinib can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Ponatinib can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Ponatinib.
SertralineThe serum concentration of Ponatinib can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Ponatinib can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ponatinib.
SiltuximabThe serum concentration of Ponatinib can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ponatinib can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Ponatinib can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Ponatinib can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Ponatinib.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Ponatinib.
SorafenibThe serum concentration of Ponatinib can be increased when it is combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Ponatinib.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Ponatinib.
SpironolactoneThe serum concentration of Ponatinib can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Ponatinib can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Ponatinib can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Ponatinib can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Ponatinib can be decreased when it is combined with Streptozocin.
SulfamethoxazoleThe metabolism of Ponatinib can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Ponatinib can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Ponatinib can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Ponatinib can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Ponatinib can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Ponatinib can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Ponatinib can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Ponatinib.
TamoxifenThe serum concentration of Ponatinib can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Ponatinib.
Taurocholic AcidThe serum concentration of Ponatinib can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ponatinib.
TelaprevirThe serum concentration of Ponatinib can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Ponatinib can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Ponatinib can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Ponatinib can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Ponatinib can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Ponatinib can be decreased when combined with Terbinafine.
TerfenadineThe serum concentration of Ponatinib can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Ponatinib can be increased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Ponatinib can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Ponatinib can be increased when it is combined with Testosterone.
ThioridazineThe metabolism of Ponatinib can be decreased when combined with Thioridazine.
TicagrelorThe serum concentration of Ponatinib can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Ponatinib can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Ponatinib.
TipranavirThe metabolism of Ponatinib can be decreased when combined with Tipranavir.
TocilizumabThe serum concentration of Ponatinib can be decreased when it is combined with Tocilizumab.
TolvaptanThe serum concentration of Ponatinib can be increased when it is combined with Tolvaptan.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ponatinib.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Ponatinib.
TranylcypromineThe metabolism of Ponatinib can be decreased when combined with Tranylcypromine.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ponatinib.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Ponatinib.
TrazodoneThe serum concentration of Ponatinib can be decreased when it is combined with Trazodone.
TrifluoperazineThe serum concentration of Ponatinib can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Ponatinib can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Ponatinib can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Ponatinib can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Ponatinib can be increased when it is combined with Troleandomycin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ponatinib.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Ponatinib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Ponatinib.
VenlafaxineThe metabolism of Ponatinib can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Ponatinib.
VerapamilThe metabolism of Ponatinib can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Ponatinib.
VinblastineThe serum concentration of Ponatinib can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Ponatinib.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ponatinib.
VincristineThe serum concentration of Ponatinib can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Ponatinib can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Ponatinib.
VoriconazoleThe serum concentration of Ponatinib can be increased when it is combined with Voriconazole.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Ponatinib.
ZimelidineThe serum concentration of Ponatinib can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Ponatinib can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Syntaxin binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 ...
Gene Name:
ABL1
Uniprot ID:
P00519
Molecular Weight:
122871.435 Da
References
  1. Iqbal Z, Aleem A, Iqbal M, Naqvi MI, Gill A, Taj AS, Qayyum A, ur-Rehman N, Khalid AM, Shah IH, Khalid M, Haq R, Khan M, Baig SM, Jamil A, Abbas MN, Absar M, Mahmood A, Rasool M, Akhtar T: Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. PLoS One. 2013;8(2):e55717. doi: 10.1371/journal.pone.0055717. Epub 2013 Feb 8. [PubMed:23409026 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Rho guanyl-nucleotide exchange factor activity
Specific Function:
GTPase-activating protein for RAC1 and CDC42. Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them. Displays serine/threonine kinase activity.
Gene Name:
BCR
Uniprot ID:
P11274
Molecular Weight:
142818.07 Da
References
  1. Iqbal Z, Aleem A, Iqbal M, Naqvi MI, Gill A, Taj AS, Qayyum A, ur-Rehman N, Khalid AM, Shah IH, Khalid M, Haq R, Khan M, Baig SM, Jamil A, Abbas MN, Absar M, Mahmood A, Rasool M, Akhtar T: Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. PLoS One. 2013;8(2):e55717. doi: 10.1371/journal.pone.0055717. Epub 2013 Feb 8. [PubMed:23409026 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1...
Gene Name:
KIT
Uniprot ID:
P10721
Molecular Weight:
109863.655 Da
References
  1. Gleixner KV, Peter B, Blatt K, Suppan V, Reiter A, Radia D, Hadzijusufovic E, Valent P: Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica. 2013 Sep;98(9):1450-7. doi: 10.3324/haematol.2012.079202. Epub 2013 Mar 28. [PubMed:23539538 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during in...
Gene Name:
RET
Uniprot ID:
P07949
Molecular Weight:
124317.465 Da
References
  1. De Falco V, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, Gozgit JM, Carlomagno F, Santoro M: Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. J Clin Endocrinol Metab. 2013 May;98(5):E811-9. doi: 10.1210/jc.2012-2672. Epub 2013 Mar 22. [PubMed:23526464 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from ...
Gene Name:
TEK
Uniprot ID:
Q02763
Molecular Weight:
125829.005 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or...
Gene Name:
FLT3
Uniprot ID:
P36888
Molecular Weight:
112902.51 Da
References
  1. Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP: Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013 Apr 18;121(16):3165-71. doi: 10.1182/blood-2012-07-442871. Epub 2013 Feb 21. [PubMed:23430109 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (...
Gene Name:
FGFR1
Uniprot ID:
P11362
Molecular Weight:
91866.935 Da
References
  1. Ren M, Hong M, Liu G, Wang H, Patel V, Biddinger P, Silva J, Cowell J, Hao Z: Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncol Rep. 2013 Jun;29(6):2181-90. doi: 10.3892/or.2013.2386. Epub 2013 Apr 4. [PubMed:23563700 ]
  2. Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM: Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7. [PubMed:23468082 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an...
Gene Name:
FGFR2
Uniprot ID:
P21802
Molecular Weight:
92024.29 Da
References
  1. Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM: Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7. [PubMed:23468082 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineraliz...
Gene Name:
FGFR3
Uniprot ID:
P22607
Molecular Weight:
87708.905 Da
References
  1. Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM: Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7. [PubMed:23468082 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in...
Gene Name:
FGFR4
Uniprot ID:
P22455
Molecular Weight:
87953.535 Da
References
  1. Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM: Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7. [PubMed:23468082 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sh2 domain binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antig...
Gene Name:
LCK
Uniprot ID:
P06239
Molecular Weight:
58000.15 Da
References
  1. Gushwa NN, Kang S, Chen J, Taunton J: Selective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors. J Am Chem Soc. 2012 Dec 19;134(50):20214-7. doi: 10.1021/ja310659j. Epub 2012 Dec 4. [PubMed:23190395 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sh3/sh2 adaptor activity
Specific Function:
Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including...
Gene Name:
SRC
Uniprot ID:
P12931
Molecular Weight:
59834.295 Da
References
  1. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028. [PubMed:19878872 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Receptor signaling protein tyrosine kinase activity
Specific Function:
Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. Functions primarily as negative regulator, but can also function as activator, depending ...
Gene Name:
LYN
Uniprot ID:
P07948
Molecular Weight:
58573.595 Da
References
  1. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028. [PubMed:19878872 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domai...
Gene Name:
KDR
Uniprot ID:
P35968
Molecular Weight:
151525.555 Da
References
  1. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028. [PubMed:19878872 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for...
Gene Name:
PDGFRA
Uniprot ID:
P16234
Molecular Weight:
122668.46 Da
References
  1. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028. [PubMed:19878872 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
Comments
comments powered by Disqus
Drug created on June 08, 2013 16:03 / Updated on September 29, 2016 02:27